128 related articles for article (PubMed ID: 32028596)
1. Healthcare Utilization and Costs after Receiving a Positive
Hao J; Hassen D; Manickam K; Murray MF; Hartzel DN; Hu Y; Liu K; Rahm AK; Williams MS; Lazzeri A; Buchanan A; Sturm A; Snyder SR
J Pers Med; 2020 Feb; 10(1):. PubMed ID: 32028596
[TBL] [Abstract][Full Text] [Related]
2. Observational study of population genomic screening for variants associated with endocrine tumor syndromes in a large, healthcare-based cohort.
Savatt JM; Ortiz NM; Thone GM; McDonald WS; Kelly MA; Berry ASF; Alvi MM; Hallquist MLG; Malinowski J; Purdy NC; Williams MS; Sturm AC; Buchanan AH
BMC Med; 2022 Jun; 20(1):205. PubMed ID: 35668420
[TBL] [Abstract][Full Text] [Related]
3. Genetics Visit Uptake Among Individuals Receiving Clinically Actionable Genomic Screening Results.
Schwartz MLB; McDonald WS; Hallquist MLG; Hu Y; McCormick CZ; Walters NL; Tsun J; Zimmerman K; Decker A; Gray C; Malinowski J; Sturm AC; Buchanan AH
JAMA Netw Open; 2024 Mar; 7(3):e242388. PubMed ID: 38488794
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of a genomic screening program for actionable genetic conditions.
Buchanan AH; Lester Kirchner H; Schwartz MLB; Kelly MA; Schmidlen T; Jones LK; Hallquist MLG; Rocha H; Betts M; Schwiter R; Butry L; Lazzeri AL; Frisbie LR; Rahm AK; Hao J; Willard HF; Martin CL; Ledbetter DH; Williams MS; Sturm AC
Genet Med; 2020 Nov; 22(11):1874-1882. PubMed ID: 32601386
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer and ovarian cancer genetics.
Edlich RF; Winters KL; Lin KY
J Long Term Eff Med Implants; 2005; 15(5):533-45. PubMed ID: 16218901
[TBL] [Abstract][Full Text] [Related]
6. Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing.
Peshkin BN; Schwartz MD; Isaacs C; Hughes C; Main D; Lerman C
Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1115-8. PubMed ID: 12376518
[TBL] [Abstract][Full Text] [Related]
7. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Friebel TM; Domchek SM; Neuhausen SL; Wagner T; Evans DG; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson G; Lynch HT; Tung N; Blum JL; Weitzel J; Rubinstein WS; Ganz PA; Couch F; Rebbeck TR
Clin Breast Cancer; 2007 Dec; 7(11):875-82. PubMed ID: 18269778
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling.
Metcalfe KA; Liede A; Hoodfar E; Scott A; Foulkes WD; Narod SA
J Med Genet; 2000 Nov; 37(11):866-74. PubMed ID: 11073541
[TBL] [Abstract][Full Text] [Related]
9. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
10. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Metcalfe KA; Birenbaum-Carmeli D; Lubinski J; Gronwald J; Lynch H; Moller P; Ghadirian P; Foulkes WD; Klijn J; Friedman E; Kim-Sing C; Ainsworth P; Rosen B; Domchek S; Wagner T; Tung N; Manoukian S; Couch F; Sun P; Narod SA;
Int J Cancer; 2008 May; 122(9):2017-22. PubMed ID: 18196574
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
[TBL] [Abstract][Full Text] [Related]
12. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
13. Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Phillips KA; Jenkins MA; Lindeman GJ; McLachlan SA; McKinley JM; Weideman PC; Hopper JL; Friedlander ML;
Clin Genet; 2006 Sep; 70(3):198-206. PubMed ID: 16922722
[TBL] [Abstract][Full Text] [Related]
14. Which factors predict proposal and uptake of psychological counselling after BRCA1/2 test result disclosure?
Maheu C; Bouhnik AD; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Lasset C; Berthet P; Fricker JP; Caron O; Luporsi E; Gladieff L; Julian-Reynier C
Psychooncology; 2014 Apr; 23(4):420-7. PubMed ID: 24127257
[TBL] [Abstract][Full Text] [Related]
15. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
[TBL] [Abstract][Full Text] [Related]
16. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.
Schwartz MD; Kaufman E; Peshkin BN; Isaacs C; Hughes C; DeMarco T; Finch C; Lerman C
J Clin Oncol; 2003 Nov; 21(21):4034-41. PubMed ID: 14581427
[TBL] [Abstract][Full Text] [Related]
17. Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations.
Kearton S; Wills K; Bunting M; Blomfield P; James PA; Burke J
Fam Cancer; 2018 Jul; 17(3):333-344. PubMed ID: 29039136
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
